DUBLIN–(BUSINESS WIRE)–The “Treatment Resistant Depression – Pipeline Insight, 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This “Treatment Resistant Depression – Pipeline Insight, 2020,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Treatment Resistant Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Treatment Resistant Depression Emerging Drugs Chapters
This segment of the Treatment Resistant Depression report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Treatment Resistant Depression Emerging Drugs
AXS-05: Axsome Therapeutics
AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of CNS disorders. AXS-05 consists of a proprietary formulation and dose of bupropion and dextromethorphan, or DM, and utilizes our metabolic inhibition technology. The DM component of AXS-05 is a non-competitive N-methyl-D-aspartate, or NMDA, receptor antagonist, also known as a glutamate receptor modulator. The DM component of AXS-05 is also a sigma-1 receptor agonist, nicotinic acetylcholine receptor antagonist, and inhibitor of the serotonin and norepinephrine transporters. The bupropion component of AXS-05 serves to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor, and a nicotinic acetylcholine receptor antagonist. AXS-05 is an investigational drug not yet approved by the FDA. (Read more…)
Psilocybin: COMPASS Pathways
Psilocybin therapy is an approach being investigated for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support. Psilocybin is an active ingredient in some species of mushrooms, often referred to as ‘magic mushrooms’. COMPASS Pathways has developed a synthesised formulation of psilocybin, COMP 360, and are investigating the effectiveness of psilocybin therapy, initially in treatment-resistant depression.
MIJ821: Novartis Pharmaceuticals
MIJ821 is a selective and potent NMDA receptor modulator that is being developed by Novartis for the treatment of Treatment-Resistant Depression. It is currently in phase II stage of development.
Treatment Resistant Depression: Therapeutic Assessment
This segment of the report provides insights about the different Treatment Resistant Depression drugs segregated based on the following parameters that define the scope of the report, such as:
Major Players in Treatment-Resistant Depression
There are approx. 40+ key companies which are developing the therapies for Treatment Resistant Depression. The companies which have their Treatment Resistant Depression drug candidates in the most advanced stage, i.e. phase III include Axsome Therapeutics and others
Phases
This report covers around 40+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Treatment Resistant Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Treatment Resistant Depression: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Treatment Resistant Depression therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Treatment Resistant Depression drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Treatment Resistant Depression R&D. The therapies under development are focused on novel approaches to treat/improve Treatment Resistant Depression.
- In April 2020, COMPASS Pathways completed a successful USD 80m Series B investment round. This funding will expand upon COMPASS’s lead programme in psilocybin therapy for treatment-resistant depression, supporting research into additional indications for psilocybin therapy, advancing the company’s preclinical pipeline, developing digital technologies, and establishing new academic and clinical research partnerships.
- Cadent Therapeutics exclusively licensed the intellectual property for compounds that selectively modulate NR2B-containing NMDA receptors to Novartis. This license included MIJ821 (CAD-9271).
Treatment Resistant Depression Report Insights
- Treatment Resistant Depression Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Treatment Resistant Depression Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
- How many companies are developing Treatment Resistant Depression drugs?
- How many Treatment Resistant Depression drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Treatment Resistant Depression?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Treatment Resistant Depression therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Treatment Resistant Depression and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Questions
- Axsome Therapeutics
- COMPASS Pathways
- Novartis Pharmaceuticals
- Millennium Pharmaceuticals
- Navitor Pharmaceuticals
- CeNeRx BioPharma
- Janssen Research & Development
Key Questions
- AXS-05
- Psilocybin
- MIJ821
- TAK-653
- NV-5138
- CX157
- EVT 101
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/3ulhd2
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900